{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T09:23:28Z","timestamp":1775208208964,"version":"3.50.1"},"reference-count":49,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T00:00:00Z","timestamp":1537747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Clinical Hypertension"],"published-print":{"date-parts":[[2018,10]]},"abstract":"Left ventricular hypertrophy develops in 36%\u201041% of hypertensive patients and independently predicts cardiovascular events and total mortality. Moreover, drug\u2010induced reduction in left ventricular mass (LVM<\/jats:styled-content>) correlates with improved prognosis. The optimal thiazide\u2010type diuretic for reducing LVM<\/jats:styled-content> is unknown. Evidence regarding potency, cardiovascular events, sodium, and potassium suggested the hypothesis that \u201cCHIP<\/jats:styled-content>\u201d diuretics (CH<\/jats:styled-content>lorthalidone, Indapamide, and Potassium\u2010sparing diuretic\/hydrochlorothiazide [PSD<\/jats:styled-content>\/HCTZ<\/jats:styled-content>]) would reduce LVM<\/jats:styled-content> more than HCTZ<\/jats:styled-content>. Systematic searches of five databases were conducted. Among the 38 randomized trials, a 1% reduction in systolic blood pressure (SBP<\/jats:styled-content>) predicted a 1% reduction in LVM<\/jats:styled-content>, P<\/jats:italic>\u00a0=\u00a00.00001. CHIP<\/jats:styled-content>\u2010HCTZ<\/jats:styled-content> differences in reducing LVM<\/jats:styled-content> differed across trials (ie, heterogeneity), making interpretation uncertain. However, among the 28 double\u2010blind trials, heterogeneity was undetectable, and HCTZ<\/jats:styled-content> reduced LVM<\/jats:styled-content> (percent reduction [95% CI<\/jats:styled-content>]) by \u22127.3 (\u221210.4, \u22124.2), P<\/jats:italic>\u00a0<\u00a00.0001. CHIP<\/jats:styled-content> diuretics surpassed HCTZ<\/jats:styled-content> in reducing LVM<\/jats:styled-content>: chlorthalidone \u22128.2 (\u221214.7, \u22121.6), P<\/jats:italic>\u00a0=\u00a00.015; indapamide \u22127.5 (\u221212.7, \u22122.3), P<\/jats:italic>\u00a0=\u00a00.005; and all CHIP<\/jats:styled-content> diuretics combined \u22127.7 (\u221212.2, \u22123.1), P<\/jats:italic>\u00a0<\u00a00.001. The comparison of PSD<\/jats:styled-content>\/HCTZ<\/jats:styled-content> with HCTZ<\/jats:styled-content> had low statistical power but favored PSD<\/jats:styled-content>\/HCTZ<\/jats:styled-content>: \u22126.0 (\u221214.1, +2.1), P<\/jats:italic>\u00a0=\u00a00.149. Thus, compared to HCTZ<\/jats:styled-content>, CHIP<\/jats:styled-content> diuretics had twice the effect on LVM<\/jats:styled-content>. CHIP<\/jats:styled-content> diuretics did not surpass HCTZ<\/jats:styled-content> in reducing systolic or diastolic blood pressure: \u22120.3 (\u22125.0, +4.3) and \u22121.6 (\u22125.6, +2.4), respectively. The strength of evidence that CHIP<\/jats:styled-content> diuretics surpass HCTZ<\/jats:styled-content> for reducing LVM<\/jats:styled-content> was high (GRADE<\/jats:styled-content> criteria). In conclusion, these novel results have demonstrated that CHIP<\/jats:styled-content> diuretics reduce LVM<\/jats:styled-content> 2\u2010fold more than HCTZ<\/jats:styled-content> among hypertensive patients. Although generally related to LVM<\/jats:styled-content>, blood pressure fails to explain the superiority of CHIP<\/jats:styled-content> diuretics for reducing LVM<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/jch.13386","type":"journal-article","created":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T06:10:05Z","timestamp":1537855805000},"page":"1507-1515","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium\u2010sparing\/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: A systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1822-813X","authenticated-orcid":false,"given":"George C.","family":"Roush","sequence":"first","affiliation":[{"name":"NYU School of Medicine New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramy","family":"Abdelfattah","sequence":"additional","affiliation":[{"name":"NYU School of Medicine New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Song","sequence":"additional","affiliation":[{"name":"SUNY Downstate Medical Center New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Ernst","sequence":"additional","affiliation":[{"name":"University of Iowa Hospital and Clinics Iowa City Iowa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenic A.","family":"Sica","sequence":"additional","affiliation":[{"name":"Department of Medicine and Pharmacology Virginia Commonwealth University Richmond Virginia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John B.","family":"Kostis","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute Rutgers Robert Wood Johnson Medical School New Brunswick New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,9,24]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2011.104"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199005313222203"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001073"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.19.2350"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.12.048"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/08037051.2013.791414"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.107.087320"},{"key":"e_1_2_8_9_1","first-page":"548","volume-title":"Robbins Pathologic Basis of Disease","author":"Schoen FJ","year":"1999"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajh.2010.80"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2009.00156.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.136655"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-015-0540-6"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.181248"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.05021"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.10.083"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-015-3469-1"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000762"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.112.191106"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.161505"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.168054"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.02.008"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.176271"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440420077006"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-007-0027-1"},{"key":"e_1_2_8_26_1","first-page":"H177","article-title":"Sodium and left ventricular mass in untreated hypertensive and normotensive subjects","volume":"263","author":"Cailar G","year":"1992","journal-title":"Am J Physiol"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.89.3.1023"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.6.5.755"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.jrn.2015.08.005"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.04.014"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.07.430"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/080370598437169"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.3109\/08037051.2011.649537"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2010.02462.x"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000178572.63064.73"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/030006057800600509"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007999609111560"},{"key":"e_1_2_8_38_1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins JPT","year":"2008"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.7326\/M13-2886"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470743386.ch16"},{"key":"e_1_2_8_41_1","unstructured":"RyanR HillS.How to GRADE the quality of the evidence. Cochrane Consumers and Communication Group;2016.http:\/\/cccrg.cochrane.org\/author-resources. Version 3.0. Accessed December 2016."},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.04.002"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001691"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.115.05138"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021716"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806182"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000203309.07140.d3"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.3109\/07420528.2010.510230"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.154476"},{"key":"e_1_2_8_50_1","unstructured":"IMS Institute for Healthcare informatics.Medicines use and spending in the U.S.: A review of 2015 and outlook to 2020. Parsippany NJ;2016."}],"container-title":["The Journal of Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjch.13386","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jch.13386","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T07:13:42Z","timestamp":1694934822000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jch.13386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,24]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1111\/jch.13386"],"URL":"https:\/\/doi.org\/10.1111\/jch.13386","archive":["Portico"],"relation":{},"ISSN":["1524-6175","1751-7176"],"issn-type":[{"value":"1524-6175","type":"print"},{"value":"1751-7176","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,24]]},"assertion":[{"value":"2018-04-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}